Nucorion Pharmaceuticals is uniquely positioned to address unmet medical needs in China, as well as other major pharmaceutical markets.
Technology
Our technology platforms utilize LTP TECHNOLOGY™, a broadly applicable liver-targeting prodrug technology, and Nucleos(t)ide Technology, which allows us to bypass mechanisms of resistance in cancer cells.
Our product pipeline currently has four programs that have been developed using our proprietary technology. Three of which are approaching Clinical Candidate status, while the fourth is near the Lead Optimization stage.
